Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of E/C/F/TAF in HIV-1 with Renal Impairment
NCT01818596Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2013
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Mar 2013; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01818596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818596.